TY - JOUR
T1 - Systemic fungal infections
T2 - A pharmacist/researcher perspective
AU - Spencer, Abbygail C.
AU - Brubaker, Katelyn R.
AU - Garneau-Tsodikova, Sylvie
N1 - Publisher Copyright:
© 2022 British Mycological Society
PY - 2023/6
Y1 - 2023/6
N2 - Systemic fungal infections are increasing in prevalence, especially in immunocompromised patients and post-surgical patients. The rise in systemic fungal infections has resulted in increased utilization of antifungal agents which, in turn, has contributed to escalating resistance rates as seen by the increasing number of fungal pathogens added to the Centers for Disease Control and Prevention Antimicrobial Resistance Threats Report in 2019. Unfortunately, there are few novel antifungal agents coming to market to combat these ever-increasing resistance rates. In this review, we cover the current climate of antifungal agents and explore agents coming through the pipeline and potentially to market. We also discuss the indicated uses for empiric and targeted antifungal therapies as well as the need to include antifungal agents as a part of antimicrobial stewardship programs that focus heavily on antibacterial agents.
AB - Systemic fungal infections are increasing in prevalence, especially in immunocompromised patients and post-surgical patients. The rise in systemic fungal infections has resulted in increased utilization of antifungal agents which, in turn, has contributed to escalating resistance rates as seen by the increasing number of fungal pathogens added to the Centers for Disease Control and Prevention Antimicrobial Resistance Threats Report in 2019. Unfortunately, there are few novel antifungal agents coming to market to combat these ever-increasing resistance rates. In this review, we cover the current climate of antifungal agents and explore agents coming through the pipeline and potentially to market. We also discuss the indicated uses for empiric and targeted antifungal therapies as well as the need to include antifungal agents as a part of antimicrobial stewardship programs that focus heavily on antibacterial agents.
KW - Antifungal agent
KW - Mechanism of action
KW - Stewardship
KW - Systemic antifungal coverage
KW - Systemic fungal infections
UR - http://www.scopus.com/inward/record.url?scp=85143504664&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85143504664&partnerID=8YFLogxK
U2 - 10.1016/j.fbr.2022.11.001
DO - 10.1016/j.fbr.2022.11.001
M3 - Review article
AN - SCOPUS:85143504664
SN - 1749-4613
VL - 44
JO - Fungal Biology Reviews
JF - Fungal Biology Reviews
M1 - 100293
ER -